phenazopyridine hydrochloride

phen·a·zo·pyr·i·dine hydrochloride (fn-z-pr-dn)

n.

An oral analgesic used to treat urinary tract pain and urgency.

---

phenazopyridine hydrochloride

AZO-Gesic, Azo-Standard, Baridium, Geridium, Phenazo (CA), Prodium, Pyridium, ReAzo, Uristat, Urogesic, UTI Relief

Pharmacologic class: Nonopioid analgesic

Therapeutic class: Urinary analgesic

Pregnancy risk category B

Action

Unknown. Thought to act locally on urinary tract mucosa to produce analgesic or anesthetic effects, relieving urinary burning, urgency, and frequency.

Availability

Tablets: 95 mg, 97.2 mg, 100 mg, 200 mg

⊘Indications and dosages

➣ Pain caused by lower urinary tract irritation

Adults: 200 mg P.O. t.i.d.

Children: 12 mg/kg P.O. daily in three divided doses

Contraindications

• Hypersensitivity to drug
• Renal insufficiency

Precautions

Use cautiously in:
• hepatitis
• pregnant or breastfeeding patients
• children younger than age 12.

Administration

• Give with or after meals.
• Discontinue after 2 days, as prescribed, when administering with antibiotics.

Route	Onset	Peak	Duration
P.O.	Unknown	Unknown	6-8 hr

Adverse reactions

CNS: headache

EENT: contact lens staining

GI: GI disturbances

GU: bright orange urine, renal toxicity

Hepatic: hepatotoxicity

Hematologic: hemolytic anemia , methemoglobinemia

Skin: rash, pruritus

Other: anaphylactoid-like reaction

Interactions

Drug-diagnostic tests. Bilirubin, glucose, ketones, protein, steroids: interference with urine tests based on spectrophotometry or color reactions

Patient monitoring

• Monitor patient for symptomatic improvement of urinary tract infection (UTI).
• Assess follow-up urine culture after antibiotic therapy ends.
☞ Monitor for yellowing of skin or sclera. This change may indicate drug accumulation caused by impaired renal excretion, warranting drug withdrawal.

Patient teaching

• Explain drug therapy and measures to help prevent UTI recurrence.
• Tell patient drug may discolor urine and tears and may stain clothing and contact lenses.
☞ Advise patient to contact prescriber promptly if symptoms don't improve or if skin or eyes become yellow.
• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the tests mentioned above.